Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance - Wikidata - wikimedia - TriplyDB

Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance

Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance

http://www.wikidata.org/entity/Q28483383

about

Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR Estimating HIV-1 fitness characteristics from cross-sectional genotype data Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay HIV-1 drug resistance and resistance testing.Using high-throughput sequencing to leverage surveillance of genetic diversity and oseltamivir resistance: a pilot study during the 2009 influenza A(H1N1) pandemic.Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing Variability of HIV-1 genomes among children and adolescents from São Paulo, Brazil Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.Molecular characterization of human T-cell lymphotropic virus type 1 full and partial genomes by Illumina massively parallel sequencing technology A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library.A Pan-HIV Strategy for Complete Genome Sequencing.HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq.Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Clinical implications of HIV-1 minority variants Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.Deep sequencing: becoming a critical tool in clinical virology.Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors.Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?HIV-1 drug-resistant minority variants: sweating the small stuff Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments

P2860

Q28537608-54C9747B-B650-45EC-A55A-6B688C86719D Q28540368-AFDF1AF1-2DF8-4DED-8DA2-175103D3A1A5 Q28541754-94F62A82-F314-4E4B-B71F-513A8FB9057A Q28543986-98261D89-0C87-44AD-86D7-44698926FCC1 Q28544753-8007E4F1-6E2A-43C0-8BC0-08D9B75789EA Q28547874-E1EB2E8A-E2F5-4F45-9EBA-AAEC27D13887 Q28551441-56099C74-4E1D-4332-8152-F9D0875FD54B Q28660673-142D47D7-8A19-490A-BD5D-951E440D4543 Q30245693-0522B36C-BAD4-46B7-8322-A7ECE41F3E42 Q30352006-128B8DCB-79BF-4C51-AABF-B07BDE04C20D Q33622927-BC89B037-B5F0-4E06-A6B4-909418D051C8 Q34567556-99273BB6-CD53-413D-B737-B7921DDF30E2 Q34717313-19794B0F-242A-45CB-BF2B-8937A86E25A5 Q34975934-36E99335-D286-44A6-98CB-F0ECEF39E999 Q34997577-91C98E92-D60F-4A55-8CDD-C7EBC3AEC463 Q35136041-97D9FFA5-3DB4-41B7-88E4-472187A1357F Q35494993-B460C3EC-238D-480C-94E2-72DCCBC8CCAE Q35877301-0042C36F-28A0-46A1-851C-536D1ABFE08F Q36158371-912EA022-E523-4B4D-99F9-3E55E01EC401 Q36271817-92FAB1EA-C907-448D-802C-46C6CBAEA6C8 Q36667504-9A1C22EF-58CF-49A9-BA8D-2CB095E71F41 Q36669337-F44FB84D-45D4-4993-9CE4-A002FE9150CC Q36811249-4E8FF729-F690-4031-8AAB-4FD82052E388 Q36933330-A82FEF71-D065-459C-9E8E-9E17F12C86C6 Q38226696-57297E85-0DC3-4411-B5D8-07D69DCB9365 Q39149710-A13AE617-80BD-4537-AF65-43442FC93BF1 Q39311297-CB36A0F0-6D9A-4716-84B8-84226B58FB10 Q41926464-6BE0C2AE-5FF1-451C-9D78-F434F7ED44D9 Q41929325-ACC72F80-53BB-45C4-9CD7-3B053B8FA791 Q42234370-FC25B41D-958B-4331-B0CC-BD228DFF936E Q42532116-9322C6CE-1E33-4A69-93B9-B16F51A64460 Q47140686-15FF2C6A-ED1F-457C-BA36-696A6B3B0565 Q47569409-E59B3442-589F-4D77-8C89-65021A3C67D4 Q47624533-9E8CDE52-7D46-4D99-80CD-15656336BA4B Q55270831-9F2F05B0-F24A-435A-821D-A702FD223D7E Q55511989-72082D08-456F-4B83-B870-D944BAAD887B Q58792426-924B5355-BC0A-4E08-B8B5-E9B30E87A7C4

P2860

Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance

http://www.wikidata.org/entity/Q28483383

description

2012 nî lūn-bûn

@nan

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@ast

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@en

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@nl

type

label

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@ast

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@en

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@nl

prefLabel

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@ast

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@en

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@nl

P1433

Q28483383-4796E5B8-4811-4AF5-9252-6C871BDE04F0

P1476

Q28483383-C2AF39E3-0446-4477-ABC4-B4C60966D569

P2093

Q28483383-099333C7-09AA-4265-9EB4-2BA111AD2A04

Q28483383-41099AD2-C522-4524-887D-6E04CDCC77A5

Q28483383-807723AF-37B0-4D8A-8B6F-9662EFF4E604

Q28483383-AA9EF758-2C50-4EA7-856E-1AEE0BD0969A

Q28483383-E3433605-488A-42B1-8C08-F004516574AF

P2860

Q28483383-1D468312-C258-4C61-B627-73C8737A0D3D

Q28483383-20D67C72-3283-4AE7-BFE9-48289CEF2C2A

Q28483383-253F0B69-DA27-4C76-B1F3-60B56DEDC5E1

Q28483383-463C81AE-56BC-4A0B-961E-4EFE21B9C470

Q28483383-4D12EC85-1A7D-4DA0-B0F8-25EDB7EA2699

Q28483383-5FF5F45B-D632-4B52-A03A-D5AE9E54B3E2

Q28483383-82433BCB-B7DC-4634-95A4-A4AF0A8D589F

Q28483383-9A33D321-FD5F-4A66-81B5-BBF1438008D0

Q28483383-A50267DC-55AE-429E-92E9-0D6B1480D720

Q28483383-A9F27BAF-48E5-447B-8F0F-22CE85C8E6D4

P304

Q28483383-1996CF63-F9AC-464B-BB15-BED9D2952EF4

P31

Q28483383-A1779BD9-235B-4907-9255-08A75DAFA9FC

P3181

Q28483383-714F00A9-4E01-43A5-97E9-161210D711BA

P356

Q28483383-8026FC32-66B7-4F3C-82DA-1FBD49C0F726

P407

Q28483383-C43C3641-F18A-4787-ADB4-217790707B26

P433

Q28483383-3BB194A5-F108-4C95-BDD1-D6A7B5912BED

P478

Q28483383-EED4B319-CE04-484A-AC2B-B94A11388026

P50

Q28483383-863E52A2-0DC4-42F6-8E24-CB2D29E693B9

Q28483383-9B10EFE2-33EE-4733-814A-CA3D9DBBE259

Q28483383-B66AE744-59E5-4A22-B785-500F523A57BA

Q28483383-CD45ED13-C72F-4EF2-88FC-80599D3DEE33

P577

Q28483383-9B4FB346-730F-417F-97DD-498CA39D8C79

P5875

Q28483383-CEDFCB2B-ACE2-4A1A-A501-8E8EAC64555D

P698

Q28483383-B2B22902-CD33-4092-BE62-9C207098E861

P932

Q28483383-6DFC3AF7-B1BE-40FB-8AF4-AD24C35FE1A0

P3181

P356

JOURNAL.PONE.0036494

P1433

P1476

Low-cost ultra-wide genotyping ...... illance of HIV drug resistance

@en

P2093

Benjamin N Bimber

http://www.w3.org/2001/XMLSchema#string

Emily N Chin

http://www.w3.org/2001/XMLSchema#string

Leandro F Tarosso

http://www.w3.org/2001/XMLSchema#string

Mariana M Sauer

http://www.w3.org/2001/XMLSchema#string

Priscilla R Costa

http://www.w3.org/2001/XMLSchema#string

P2860

The Bioperl toolkit: Perl modules for the life sciences

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure

The Sequence Alignment/Map format and SAMtools

HIV drug resistance surveillance using pooled pyrosequencing

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy

Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation

Characterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in São Paulo, Brazil

Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure

Fast and accurate long-read alignment with Burrows-Wheeler transform

P304

e36494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2234319

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0036494

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

David H. O’Connor

Sabri Saeed Sanabani

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224934091

http://www.w3.org/2001/XMLSchema#string

P698

22574170

http://www.w3.org/2001/XMLSchema#string

P932

3344889

http://www.w3.org/2001/XMLSchema#string